These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 11524817)

  • 41. Recommendations on the use of 18F-FDG PET in oncology.
    Fletcher JW; Djulbegovic B; Soares HP; Siegel BA; Lowe VJ; Lyman GH; Coleman RE; Wahl R; Paschold JC; Avril N; Einhorn LH; Suh WW; Samson D; Delbeke D; Gorman M; Shields AF
    J Nucl Med; 2008 Mar; 49(3):480-508. PubMed ID: 18287273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The contribution of PET to radiation treatment planning].
    Belkacémi Y; Lartigau E; Kerrou K; Carpentier P; Taïeb S; Giraud P
    Bull Cancer; 2007 Jan; 94(1):99-108. PubMed ID: 17237010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
    Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
    J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New functional imaging technique "positron emission tomography"].
    Tamaki N
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):101-4. PubMed ID: 9612703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Role of 18F-FDG positron emission tomography in surgical evaluation].
    Franzius C; Sciuk J; Schober O
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():261-9. PubMed ID: 9931622
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Added value of positron emission tomography with fluoro-18-deoxyglucose as the tracer (FDG-PET) in clinical problem cases in oncology].
    Soepenberg O
    Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1979-80. PubMed ID: 11048563
    [No Abstract]   [Full Text] [Related]  

  • 49. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
    Nestle U; Kremp S; Grosu AL
    Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?
    Hoegerle S; Juengling F; Otte A; Altehoefer C; Moser EA; Nitzsche EU
    Radiology; 1998 Oct; 209(1):253-8. PubMed ID: 9769840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PET imaging in oncology.
    Bar-Shalom R; Valdivia AY; Blaufox MD
    Semin Nucl Med; 2000 Jul; 30(3):150-85. PubMed ID: 10928381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iatrogenic FDG foci in the lungs: a pitfall of PET image interpretation.
    Hany TF; Heuberger J; von Schulthess GK
    Eur Radiol; 2003 Sep; 13(9):2122-7. PubMed ID: 12928963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Usefulness of FDG-PET in diagnosing primary lymphoma of the liver.
    Bangerter M; Moog F; Griesshammer M; Merkle E; Hafner M; Ellenrieder V; Reske SN; Heimpel H
    Int J Hematol; 1997 Dec; 66(4):517-20. PubMed ID: 9479878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical applications of FDG-PET in oncology.
    Czernin J
    Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonprosthesis orthopedic applications of (18)F fluoro-2-deoxy-D-glucose PET in the detection of osteomyelitis.
    Meller J; Sahlmann CO; Liersch T; Hao Tang P; Alavi A
    Radiol Clin North Am; 2007 Jul; 45(4):719-33, vii-viii. PubMed ID: 17706536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Usefulness of FDG-PET for the diagnosis of brain tumors].
    Bobek-Billewicz B; Jurkowski MK; Romanowicz G
    Przegl Lek; 2005; 62(1):54-60. PubMed ID: 16053223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDG imaging.
    Coleman RE
    Nucl Med Biol; 2000 Oct; 27(7):689-90. PubMed ID: 11091113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Positron emission tomography in oncology].
    Hatazawa J; Higuchi I; Nakamura H
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):748-54. PubMed ID: 12852339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FDG and Beyond.
    De Ruysscher D; Haustermans K; Thorwarth D
    Recent Results Cancer Res; 2016; 198():163-73. PubMed ID: 27318686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Positron emission tomography in the Netherlands: need to expand the capacity].
    Comans EF; Smit EF
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1817-9. PubMed ID: 12382364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.